Floatz logo

PANITUMUMAB

Migraine With Aura

Azienda Usl di Bolognamonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Migraine With Aura cohort.

Asset / SponsorPhaseRating
Dihydroergotamine mesylate
Satsuma Pharmaceuticals, Inc.
Phase 3BB
Rimegepant
University of South Florida
Phase 4BB
Treximet®
University of Aarhus
Phase 3BB
METOCLOPRAMIDE
Assistance Publique - Hôpitaux de Paris
Phase 4BB
Tonabersat
Minster Research Ltd
Phase 2B

View all 43 →

Same molecule, other indications

PANITUMUMAB is also rated in:

neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →